ESTRADIOL VALERATE; ESTRADIOL VALERATE; DIENOGEST
Clinical safety rating: avoid
Inducers of CYP450 enzymes (eg carbamazepine) may decrease estrogen levels Increases risk of thromboembolic disorders and endometrial cancer.
Estradiol valerate is a prodrug of estradiol, an estrogen receptor agonist. Dienogest is a progestin with partial antiandrogenic activity, acting as a progesterone receptor agonist with antiovulatory and endometrial antiproliferative effects.
| Metabolism | Estradiol valerate is hydrolyzed to estradiol and valeric acid; estradiol undergoes hepatic metabolism via CYP3A4 to estrone and estriol. Dienogest is metabolized primarily via CYP3A4 to inactive metabolites. |
| Excretion | Estradiol valerate and dienogest: Urinary excretion accounts for approximately 50-60% of total clearance, primarily as glucuronide conjugates of estradiol and dienogest metabolites. Fecal/biliary excretion accounts for 30-40% of dienogest and its metabolites. For estradiol valerate, about 30% of metabolites are excreted in bile and feces. |
| Half-life | Estradiol valerate: Terminal half-life is approximately 13-14 hours for estradiol. Dienogest: Terminal half-life is about 10-11 hours. The combination allows for once-daily dosing with sustained hormone levels. |
| Protein binding | Estradiol: Approximately 97-99% bound, mainly to sex hormone-binding globulin (SHBG) and albumin. Dienogest: About 90-91% bound to albumin, not SHBG. Estradiol valerate increases SHBG levels. |
| Volume of Distribution | Estradiol: Vd approximately 0.6-0.7 L/kg. Dienogest: Vd approximately 0.8-1.0 L/kg. These values indicate distribution into total body water and some tissue binding. |
| Bioavailability | Estradiol valerate: Oral bioavailability is approximately 10-15% due to extensive first-pass metabolism. Dienogest: Oral bioavailability is about 90% due to minimal first-pass effect. |
| Onset of Action | Oral: Clinical effects (e.g., cycle control, endometrial changes) begin within 24-48 hours of first dose. Suppression of ovulation may take several days to establish with continuous dosing. |
| Duration of Action | Oral: Duration is 24 hours due to once-daily dosing. Clinical effect on endometrium and ovulation suppression is maintained with continuous daily administration. Withdrawal bleeding occurs during the 7-day placebo interval. |
| Molecular Weight | Estradiol valerate: 398.56 Da; Estradiol valerate (component 2): 398.56 Da; Dienogest: 311.42 Da |
One tablet daily containing estradiol valerate 2 mg and dienogest 3 mg (oral).
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment recommended; use with caution in severe renal impairment. |
| Liver impairment | Contraindicated in Child-Pugh C; avoid in Child-Pugh A and B due to lack of data. In mild hepatic impairment, use with caution if benefit outweighs risk. |
| Pediatric use | Not indicated in pediatric patients; no established dosing. |
| Geriatric use | Not indicated for postmenopausal women; consider lower dose estradiol if needed for vasomotor symptoms with careful monitoring. |
| 1st trimester | Contraindicated: risk of fetal harm including cardiovascular and urogenital abnormalities; sex hormones cross placenta and may cause teratogenic effects. |
| 2nd trimester | Contraindicated: continued risk of adverse effects on fetal development, including potential feminization of male fetuses and cardiovascular defects. |
| 3rd trimester | Contraindicated: late pregnancy use may result in genitourinary tract abnormalities and other adverse outcomes; high doses may cause masculinization of female fetuses. |
Clinical note
Inducers of CYP450 enzymes (eg carbamazepine) may decrease estrogen levels Increases risk of thromboembolic disorders and endometrial cancer.
| FDA category | Positive |
| Placental transfer | Estradiol valerate and dienogest cross the placenta; evidence from animal studies and human data shows significant transfer, with estradiol metabolized in placenta and dienogest reaching fetal circulation. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combined hormonal contraceptives. Women over 35 who smoke should not use.
| Common Effects | osteoporosis prevention |
| Serious Effects |
Known or suspected pregnancyBreastfeedingHistory of or current venous thromboembolismActive or history of arterial thromboembolic disease (e.g., stroke, myocardial infarction)Diabetes mellitus with vascular involvementSevere hypertensionHistory of migraine with focal neurological symptomsCurrent or history of breast cancer or other estrogen-dependent neoplasiaActive liver disease or history of liver tumors (benign or malignant)Undiagnosed abnormal genital bleedingHypersensitivity to any component
| Precautions | Thrombotic disorders (venous thromboembolism, arterial thrombosis), Cerebrovascular disease, Hepatic tumors (benign or malignant), Gallbladder disease, Hypertension, Carbohydrate/lipid effects, Uterine bleeding irregularities, Depression, Contact lens intolerance |
Loading safety data…
| Breastfeeding | Estradiol valerate and dienogest are excreted in breast milk in small amounts; potential for adverse effects in nursing infants including jaundice and breast enlargement; use during breastfeeding is not recommended. Dienogest may reduce milk production and quality. |
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | Pregnancy category X. Use is contraindicated during pregnancy. First trimester: exposure associated with increased risk of congenital anomalies including cardiovascular defects, limb reduction defects, and hypospadias. Second and third trimesters: potential feminization of male fetus, vaginal adenosis, and cervical/vaginal cancer later in life. Estrogens and progestins are not recommended for use during pregnancy. |
| Fetal Monitoring | Before and during therapy: pregnancy test to exclude pregnancy (highly recommend monthly). Monitor for signs of thromboembolism, hypertension, depression, and glucose intolerance. In case of accidental exposure during pregnancy, ultrasound to assess fetal development. |
| Fertility Effects | Suppresses ovulation and thus impairs fertility. After discontinuation, return to normal fertility is generally prompt, but may be delayed in some women. No permanent effects on fertility. |
| Food/Dietary | Avoid grapefruit juice as it may increase estrogen levels. Take with food to reduce nausea. No other significant food interactions. |
| Clinical Pearls | Monitor for thromboembolic events, especially in smokers over 35. Use lowest effective dose for shortest duration. Not for use in menopausal hormone therapy alone. Consider CYP3A4 inducer/inhibitor interactions. Obtain periodic blood pressure and glucose monitoring. |
| Patient Advice | Take at the same time daily with food to reduce GI upset. · Be aware of increased risk of blood clots, especially if you smoke or are over 35. · Do not use during pregnancy or breastfeeding. · Report any unusual bleeding, chest pain, or leg swelling immediately. · Use non-hormonal contraception if needed, as this drug may reduce effectiveness of hormonal contraceptives. |